References
- Aruna AS, Murungi JH. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient. Ann Pharmacother 2005; 39: 1131–1135
- Benaissa ML, Bekka R, Baud FJ. Acute cardiac failure in a case of rapidly lethal neuroleptic malignant syndrome. Intensive Care Med 1998; 24: 86–94
- Bottai T, Quintin P, Perrin E. Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry 2005; 20: 349–357
- Caroff SN. The neuroleptic malignant syndrome. J Clin Psychiatry 1980; 41: 79–83
- Caroff SE, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77: 185–202
- Cihan AY, Pabinger I. Metabolic syndrome and venous thrombosis: potential role of microparticles. Haematologica 2007; 92: 92e065
- Chu PC, Lin MT, Shian LR, Leu SY. Alteration in physiologic functions and in brain monoamine content in streptozocin-diabetic rats. Diabetes 1986; 35: 481–485
- Das Undurtion. Insulin: an endogenous cardioprotector. Curr Opin Crit Care 2003; 9: 375–383
- de Boer C, Gaete HP. Neuroleptic malignant syndrome and diabetic keto-acidosis. Br J Psychiatry 1992; 161: 856–858
- Fiebel JH, Schiffer RB. Sympathoadrenomedullary hyperactivity in the neuroleptic malignant syndrome. Am J Psychiatr 1981; 138: 1115–1156
- Goethe JW, Szarek BL, Caley CF, Woolley SB. Signs and symptoms associated with the metabolic syndrome in psychiatric inpatients receiving antipsychotics: a retrospective chart review. J Clin Psychiatry 2007; 68: 22–28
- Hadad E, Weinbroum AA, Ben-Abraham R. Drug-induced hyperthermia and muscle rigidity: a practical approach. Eur J Emerg Med 2003; 10: 149–154
- Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155: 11131–1136
- Hayashi Y, Ibe T, Kawato H, et al. Postpartum acute myocardial infarction induced by ergonovine administration. Intern Med 2003; 42: 983–986
- Lenler-Petersen P, Hansen BD, Hasselstrom. A rapidly progressing lethal case of neuroleptic malignant syndrome. Intensive Care Med 1990; 16: 267–268
- Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry 1985; 142: 1137–1145
- Mieno S, Asada K, Horimoto H, Sasaki S. Neuroleptic malignant syndrome following cardiac surgery: successful treatment with dantrolene. Eur J Cardiothorac Surg 2003; 24: 458–460
- Saeki H, Muneta S, Kobayashi T. Malignant syndrome associated with disseminated intravascular coagulation and a high level of amylase in serum, followed by diabetic coma in an elderly patient with Parkinson's disease during L-dopa therapy. Nippon Ronen Igakkai Zasshi 1998; 35: 139–144
- Saller CF, Kopin IJ. Glucose potentiates haloperidol induced catalepsy. Life Sci 1981; 29: 2337–2341
- Sato Y, Honda Y, Asoh T, Iwamoto J, Kanoko T, Satoh K. Cardiac involvement in malignant syndrome in Parkinson's disease. Eur Neurol 2005; 54: 88–92
- Shalev A, Munitz H. The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 1986; 73: 337–347
- Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. J Clin Psychiatry 1989; 50: 18–25
- Sparrow P, Murnaghan D, Kearney P, Hogan J, Sheppard MN. Acute cardiac failure in neuroleptic malignant syndrome. Eur J Heart Fail 2003; 5: 575–578
- Szukalski B, Lipska B, Welbel L, Nurowska K. Serum levels and clinical response in long–term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology (Berlin) 1986; 89: 428–431